KIR/KIR-ligand genotypes and clinical outcomes following chemoimmunotherapy in patients with relapsed or refractory neuroblastoma: a report from the Children’s Oncology Group

BACKGROUND: In the Children’s Oncology Group ANBL1221 phase 2 trial for patients with first relapse/first declaration of refractory high-risk neuroblastoma, irinotecan and temozolomide (I/T) combined with either temsirolimus (TEMS) or immunotherapy (the anti-GD2 antibody dinutuximab (DIN) and granul...

Descripción completa

Detalles Bibliográficos
Autores principales: Erbe, Amy K, Diccianni, Mitch B, Mody, Rajen, Naranjo, Arlene, Zhang, Fan F, Birstler, Jen, Kim, KyungMann, Feils, Arika S, Hung, Jung-Tung, London, Wendy B, Shulkin, Barry L, Mathew, Varsha, Parisi, Marguerite T, Servaes, Sabah, Asgharzadeh, Shahab, Maris, John M, Park, Julie, Yu, Alice L, Sondel, Paul M, Bagatell, Rochelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9950969/
https://www.ncbi.nlm.nih.gov/pubmed/36822669
http://dx.doi.org/10.1136/jitc-2022-006530

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9950969/
https://www.ncbi.nlm.nih.gov/pubmed/36822669
http://dx.doi.org/10.1136/jitc-2022-006530

Ejemplares similares